Graciela Cárdenas, María Chávez-Canales, Ana María Espinosa, Antonio Jordán-Ríos, Daniel Anica Malagon, Manlio Fabio Márquez Murillo, Laura Victoria Torres Araujo, Ricardo Leopoldo Barajas Campos, Rosa María Wong-Chew, Luis Esteban Ramirez González, Karent Ibet Cresencio, Enrique García Velázquez, Mariana Rodriguez de la Cerda, Yoana Leyva, Joselin Hernández-Ruiz, María Luisa Hernández-Medel, Mireya León-Hernández, Karen Medina Quero, Anahí Sánchez Monciváis, Eduardo Beltrán Sarmiento, Rafael Ignacio Aguilar Reynoso, Daniela Murillo Reyes, Luis Rodrigo Del Río Ambriz, Juan Salvador García Hernández, Jocelyn Cruz, Sergio Iván Valdés Ferrer, Leonor Huerta, Nora Alma Fierro, Marisela Hernández, Mayra Pérez-Tapia, Gabriela Meneses, Gabriela Rosas, Juan Alberto Hernández-Aceves, Jaquelynne Cervantes-Torres, Ricardo A Valdez, Anai Fuentes Rodríguez, Erick Espíndola-Arriaga, Mauricio Ortiz, Evelyn Alvarez Salazar, Carlos Castellanos Barba, Hugo Besedovsky, Marta C Romano, Helgi Jung, Raúl J Bobes, Gloria Soldevila, Juan C López-Alvarenga, Gladis Fragoso, Juan Pedro Laclette, Edda Sciutto
BACKGROUND: SARS-CoV2 induces flu-like symptoms that can rapidly progress to severe acute lung injury and even death. The virus also invades the central nervous system (CNS), causing neuroinflammation and death from central failure. Intravenous (IV) or oral dexamethasone (DXM) reduced 28 d mortality in patients who required supplemental oxygen compared to those who received conventional care alone. Through these routes, DMX fails to reach therapeutic levels in the CNS. In contrast, the intranasal (IN) route produces therapeutic levels of DXM in the CNS, even at low doses, with similar systemic bioavailability...
January 29, 2024: Archives of Medical Research